Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255586 | PMC |
| http://dx.doi.org/10.1007/s40120-025-00758-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor.
Cell Metab
September 2025
Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada. Electronic address:
Glucagon-like peptide 1 receptor (GLP-1R) agonists exhibit anti-inflammatory actions, yet the importance of direct immune cell GLP-1R signaling remains uncertain. Although T cells respond to GLP-1, low receptor abundance and suboptimal antisera complicate efforts to characterize immune cell GLP-1R signaling. Here, we evaluate three frequently utilized GLP-1R antibodies, revealing that one of several antibodies, AGR-021, lack ideal specificity for detecting the GLP-1R in mice.
View Article and Find Full Text PDFGD2T cells as a platform for single-dose and long-term delivery of biologics.
Nat Commun
August 2025
State Key Laboratory of Molecular Oncology, Tsinghua University, Beijing, China.
The efficacy of biologics, such as peptide and protein drugs, is often limited by their short half-lives in vivo, necessitating repeated infusions to maintain therapeutic effects. Here, we demonstrate that long-lived CAR T cells can be leveraged as a versatile platform for long-term delivery of biologics. Our recent findings show that the depletion of BCOR and ZC3H12A induces GD2 CAR T cells into an immortal-like and functional state, which we have termed GD2T cells.
View Article and Find Full Text PDFDiet quality and nutrient distribution while using glucagon-like-peptide-1 receptor agonist: A secondary cross-sectional analysis.
Obes Pillars
December 2025
GNC Holdings, LLC, 75 Hooper Place, Pittsburgh, PA, 15222, USA.
Background: With the rise of glucagon-like-peptide-1 receptor agonist medications (GLP-1RA) for obesity treatment, understanding diet quality can be a valuable tool for providing evidence-based nutrition guidance. However, there is limited data on dietary intake during GLP-1RA treatment. Thus, we analyzed diet quality and nutrient timing while using GLP-1RA.
View Article and Find Full Text PDFGLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.
Eur J Clin Pharmacol
August 2025
Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa Bay Regional Campus, Clearwater, FL, USA.
Background: Psoriasis is a chronic inflammatory skin disease driven by immune dysregulation and often exacerbated by metabolic comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes mellitus (T2DM) and weight management, have emerged as a promising treatment due to their anti-inflammatory and immunomodulatory properties.
Purpose: This review evaluates the clinical efficacy, mechanisms of action, and limitations of GLP-1RAs, such as liraglutide, exenatide, and semaglutide, in the management of psoriasis.
Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale.
Int Med Case Rep J
August 2025
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, 09124, Italy.
Purpose: To report a case of non-arteritic ischemic optic neuropathy (NAION) in an otherwise healthy patient treated with Glucagon-Like Peptide-1 (GLP-1) receptor agonists (RAs) liraglutide and semaglutide.
Observations: A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.